Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Zydus

    Jump to

    • Delhi High Court allows Zydus to sell cheaper biosimilar of cancer drug Nivolumab in public interest

      The latest ruling comes just four months ahead of the expiry of BMS' patent on Nivolumab, sold under the brand name Opdiva, which is due to lapse on May 2, 2026.

    • Zydus enters biologics CDMO with acquisitions valued at $125 million

      The deal involves an upfront payment of $75 million, with an additional contingent payment of up to $50 million over three years

    • Nifty Pharma settles 2% higher on exclusion from Trump's reciprocal tariffs; Lupin, IPCA Labs up 5%

      In recent past, U.S President Trump had signalled at potential tariffs on pharma imports as well, calling for bringing overseas manufacturing back to America.

    • Indian pharma players can deliver 100 new drugs by 2047: Zydus Chairman

      Speaking at an event, he stressed the need for innovation, capability building, and a focus on societal benefit.

    • Trump Tariff – How much can it hurt Indian pharma?

      The first order impact will be a slow market share gain from innovators after a generic launch

    • Stocks on Radar | Mankind Pharma, Zydus Lifesciences, Ashoka Buildcon, Hero Motocorp in Focus

      Stocks on radar October 03: Let's catch up on the latest news from the stock market. From significant investments to major deals, fundraising and appointments, here’s a quick look at which stocks will be in focus in today's trade

    • Zydus Lifesciences to buy Perfect Day's 50% stake in Sterling Biotech to forge a 50:50 JV

      For Zydus, this acquisition marks a strategic foray into specialized biotech products targeting health and nutrition, particularly for consumers who prefer animal-free protein or are lactose intolerant.

    • Zydus gets Mexican regulatory approval to market cancer treatment product

      Following the approval by Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), for Mamitra, the drug will be marketed in different strengths of 150 mg and 440 mg, Zydus Lifesciences said in a regulatory filing.

    • Zydus Lifesciences gets USFDA nod for generic drug to prevent chest pain in heart patients

      The approval by the US Food and Drug Administration (USFDA) is to manufacture and market Isosorbide Mononitrate Extended-Release, of strengths 30 mg, 60 mg, and 120 mg, Zydus Lifesciences said in a regulatory filing.

    • Zydus launches pill for prostate cancer patients

      Prostate cancer is one of the leading cancers in men and more than 43,000 cases were reported in India in 2022 as per the National Cancer Registry Program of India.

    • Zydus gets USFDA nod for generic medication for postherpetic neuralgia

      The drug maker is the first company to receive final approval for generic Gabapentin tablets (300 mg and 600 mg), it added. The product will be launched immediately in the US market, the drug firm stated.

    • Zydus Life subsidiary gets Income Tax demand of Rs 280 cr

      ZHL does not expect the said intimation to have any material financial impact as the above-mentioned adjustments are not sustainable in law and are wholly defendable on the facts of the case, the company added

    • Zydus gets USFDA nod for antiviral drug used in HIV treatment

      The company has received final approval from the US Food and Drug Administration (USFDA) for Darunavir Tablets, the company said in a statement.

    • Zydus receives final approval from USFDA for Methylene Blue Injection

      The majority of current market usage is still on the ampoule presentation whereas Zydus is offering a generic version of Methylene Blue injection in vial presentation, the pharma company said.

    • Zydus Lifesciences: Why we are getting constructive

      There is a steady progress in product approvals and clinical trials for Zydus' niche products meant for rare ailments

    • Lupin, Zydus Lifesciences ink licensing and supply pact for Saroglitazar Mg

      Saroglitazar Mg, approved by the DCGI, is an innovative drug from Zydus to treat chronic liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steato Hepatitis (NASH).

    • Zydus Life to acquire LiqMeds Group for Rs 689 crore

      Zydus added that LiqMeds Group has capabilities and specialisation in development, manufacturing and supply of oral liquid products for global markets, which it currently commercializes through partners.

    • Zydus, Sun Pharma to co-market oral drug for anaemia linked to kidney diseases

      Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease in India.

    • Moneycontrol Selects: Top stories this evening

    • Zydus Lifesciences: Time to book profit, post strong rally over a year?

    • Delhi HC bars Zydus Wellness from using ‘SugarLite’ brand name

    • Zydus recalls over 55,000 bottles of generic drug in US

    • Zydus Lifesciences gets USFDA nod to market generic drug to lower cholesterol levels

    • Zydus, Medtronic partner for first AI-based stroke care network in Gujarat

    • Zydus, Baba Ramdev firm among 16 barred from selling drugs in Nepal

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347